AVCT Avacta Group Plc

TIDMAVCT

Avacta Group PLC

19 October 2017

19 October 2017

Avacta Group plc

("Avacta" or "the Company")

Private Shareholder Update Event

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, will be hosting a Private Shareholder event on Wednesday, 15 November 2017 at 2.00 pm until 4.00 pm at finnCap's offices, 60 New Broad St, London EC2M 1JJ and will take the form of a Company presentation to update shareholders on progress followed by a Q&A session.

The presentation for the event will also be made available on the Company's website.

Investors and shareholders who wish to attend the event should register their interest at:

investorevents@avacta.com

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0) 
  Alastair Smith, Chief Executive         844 414 0452 
  Officer                                 www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                             Tel: +44 (0) 
  Geoff Nash / Giles Rolls - Nominated    207 220 0500 
  Adviser                                 www.finncap.com 
  Tim Redfern / Alice Lane / Nikita 
  Jain - Corporate Broking 
 
  WG Partners                             Tel: +44 (0) 
  Nigel Birks / Nigel Barnes              203 705 9318 
  David Wilson / Claes Spang              Tel: +44 (0) 
                                          203 705 9217 
                                          www.wgpartners.co.uk 
 Zyme Communications (Trade and          Tel: +44 (0)7787 
  Regional Media)                         502 947 
  Katie Odgaard                           katie.odgaard@zymecommunications.com 
 
  Yellow Jersey (Financial Media          Tel: +44 (0)7764 
  and IR)                                 947137 
  Sarah Hollins                           avacta@yellowjerseypr.com 
 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGGRWUUPMURR

(END) Dow Jones Newswires

October 19, 2017 02:00 ET (06:00 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024

Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024